International Journal of Hepatology最新文献_第9页

Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials. 非甾体抗炎药的肝毒性:随机对照试验的系统评价。

IF 1.8

International Journal of Hepatology Pub Date : 2018-01-15 eCollection Date: 2018-01-01 DOI: 10.1155/2018/5253623

Pajaree Sriuttha, Buntitabhon Sirichanchuen, Unchalee Permsuwan

{"title":"Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials.","authors":"Pajaree Sriuttha, Buntitabhon Sirichanchuen, Unchalee Permsuwan","doi":"10.1155/2018/5253623","DOIUrl":"https://doi.org/10.1155/2018/5253623","url":null,"abstract":"Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely used medication in several countries, including Thailand. NSAIDs have been associated with hepatic side effects; however, the frequency of these side effects is uncertain.Aim of the review: To systematically review published literature on randomized, controlled trials that assessed the risk of clinically significant hepatotoxicity associated with NSAIDs.Methods: Searches of bibliographic databases EMBASE, PubMed, and the Cochrane Library were conducted up to July 30, 2016, to identify randomized controlled trials of ibuprofen, naproxen, diclofenac, piroxicam, meloxicam, mefenamic acid, indomethacin, celecoxib, and etoricoxib in adults with any disease that provide information on hepatotoxicity outcomes.Results: Among the 698 studies, 18 studies met the selection criteria. However, only 8 studies regarding three NSAIDs (celecoxib, etoricoxib, and diclofenac) demonstrated clinically significant hepatotoxic evidence based on hepatotoxicity justification criteria. Of all the hepatotoxicity events found from the above-mentioned three NSAIDs, diclofenac had the highest proportion, which ranged from 0.015 to 4.3 (×10-2), followed by celecoxib, which ranged from 0.13 to 0.38 (×10-2), and etoricoxib, which ranged from 0.005 to 0.930 (×10-2).Conclusion: Diclofenac had higher rates of hepatotoxic evidence compared to other NSAIDs. Hepatotoxic evidence is mostly demonstrated as aminotransferase elevation, while liver-related hospitalization or discontinuation was very low.","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2018 ","pages":"5253623"},"PeriodicalIF":1.8,"publicationDate":"2018-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/5253623","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35940667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 88

HCV Integrated Care: A Randomized Trial to Increase Treatment Initiation and SVR with Direct Acting Antivirals. HCV综合护理:一项随机试验，以增加直接作用抗病毒药物的治疗起始和SVR。

IF 1.8

International Journal of Hepatology Pub Date : 2017-01-01 Epub Date: 2017-07-27 DOI: 10.1155/2017/5834182

Erik J Groessl, Lin Liu, Marisa Sklar, Samuel B Ho

{"title":"HCV Integrated Care: A Randomized Trial to Increase Treatment Initiation and SVR with Direct Acting Antivirals.","authors":"Erik J Groessl, Lin Liu, Marisa Sklar, Samuel B Ho","doi":"10.1155/2017/5834182","DOIUrl":"https://doi.org/10.1155/2017/5834182","url":null,"abstract":"Background and aims: Psychiatric or substance use disorders are barriers to successful HCV antiviral treatment. In a randomized, controlled trial (RCT), the effects of HCV Integrated Care (IC) for increasing treatment rates and sustained viral response (SVR) were studied with direct acting antivirals (DAA).Methods: In 2012-13, VA patients, whose screening was positive for depression, PTSD, or substance use (N = 79), were randomized to IC or Usual Care (UC). IC consisted of brief psychological interventions and case management. The primary endpoint was SVR among patients followed for an average of 16.6 months.Results: 42% of the study participants were previously homeless and 79% had HCV genotype 1. Twice as many IC participants (45%) initiated treatment compared with UC participants (23%) (χ2 = 4.59, p = 0.032). Among those treated, SVR rates did not significantly differ (IC: 12/18 = 67%; UC: 5/9 = 55%; p = 0.23). Among all randomized participants, IC participants trended toward better SVR rates (30.0% versus 12.8% in UC; p = 0.07).Conclusions: Although first-generation DAAs are no longer used, this smaller RCT helps confirm the results of a larger multisite RCT showing that Integrated Care results in higher treatment initiation and SVR rates among HCV-infected persons with comorbid psychological disorders. Integrated mental health services can facilitate treatment among the most challenging HCV patients, many of whom have not been successfully treated. This trial is registered with ClinicalTrials.gov number NCT00722423.","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2017 ","pages":"5834182"},"PeriodicalIF":1.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/5834182","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35280502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Predictive Factors for a Long Hospital Stay in Patients Undergoing Laparoscopic Cholecystectomy. 腹腔镜胆囊切除术患者住院时间过长的预测因素。

IF 1.8

International Journal of Hepatology Pub Date : 2017-01-01 Epub Date: 2017-01-23 DOI: 10.1155/2017/5497936

Wasana Ko-Iam, Trichak Sandhu, Sahattaya Paiboonworachat, Paisal Pongchairerks, Anon Chotirosniramit, Narain Chotirosniramit, Kamtone Chandacham, Tidarat Jirapongcharoenlap, Sunhawit Junrungsee

{"title":"Predictive Factors for a Long Hospital Stay in Patients Undergoing Laparoscopic Cholecystectomy.","authors":"Wasana Ko-Iam, Trichak Sandhu, Sahattaya Paiboonworachat, Paisal Pongchairerks, Anon Chotirosniramit, Narain Chotirosniramit, Kamtone Chandacham, Tidarat Jirapongcharoenlap, Sunhawit Junrungsee","doi":"10.1155/2017/5497936","DOIUrl":"10.1155/2017/5497936","url":null,"abstract":"Background. Although the advantages of laparoscopic cholecystectomy (LC) over open cholecystectomy are immediately obvious and appreciated, several patients need a postoperative hospital stay of more than 24 hours. Thus, the predictive factors for this longer stay need to be investigated. The aim of this study was to identify the causes of a long hospital stay after LC. Methods. This is a retrospective cohort study with 500 successful elective LC patients being included in the analysis. Short hospital stay was defined as being discharged within 24 hours after the operation, whereas long hospital stay was defined as the need for a stay of more than 24 hours after the operation. Results. Using multivariable analysis, ten independent predictive factors were identified for a long hospital stay. These included patients with cirrhosis, patients with a history of previous acute cholecystitis, cholangitis, or pancreatitis, patients on anticoagulation with warfarin, patients with standard-pressure pneumoperitoneum, patients who had been given metoclopramide as an intraoperative antiemetic drug, patients who had been using abdominal drain, patients who had numeric rating scale for pain > 3, patients with an oral analgesia requirement > 2 doses, complications, and private ward admission. Conclusions. LC difficulties were important predictive factors for a long hospital stay, as well as medication and operative factors.","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2017 ","pages":"5497936"},"PeriodicalIF":1.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292377/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34765955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Shorter Leukocyte Telomere Length in Relation to Presumed Nonalcoholic Fatty Liver Disease in Mexican-American Men in NHANES 1999-2002. NHANES 1999-2002中，墨西哥裔美国男性白细胞端粒长度较短与推定的非酒精性脂肪肝有关。

IF 1.8

International Journal of Hepatology Pub Date : 2017-01-01 Epub Date: 2017-06-27 DOI: 10.1155/2017/8435178

Janet M Wojcicki, David Rehkopf, Elissa Epel, Philip Rosenthal

{"title":"Shorter Leukocyte Telomere Length in Relation to Presumed Nonalcoholic Fatty Liver Disease in Mexican-American Men in NHANES 1999-2002.","authors":"Janet M Wojcicki, David Rehkopf, Elissa Epel, Philip Rosenthal","doi":"10.1155/2017/8435178","DOIUrl":"https://doi.org/10.1155/2017/8435178","url":null,"abstract":"Leukocyte telomere length is shorter in response to chronic disease processes associated with inflammation such as diabetes mellitus and coronary artery disease. Data from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2002 was used to explore the relationship between leukocyte telomere length and presumed NAFLD, as indicated by elevated serum alanine aminotransferase (ALT) levels, obesity, or abdominal obesity. Logistic regression models were used to evaluate the relationship between telomere length and presumed markers of NAFLD adjusting for possible confounders. There was no relationship between elevated ALT levels, abdominal obesity, or obesity and telomere length in adjusted models in NHANES (OR 1.13, 95% CI 0.48-2.65; OR 1.17, 95% CI 0.52-2.62, resp.). Mexican-American men had shorter telomere length in relation to presumed NAFLD (OR 0.07, 95% CI 0.006-0.79) and using different indicators of NAFLD (OR 0.012, 95% CI 0.0006-0.24). Mexican origin with presumed NAFLD had shorter telomere length than men in other population groups. Longitudinal studies are necessary to evaluate the role of telomere length as a potential predictor to assess pathogenesis of NALFD in Mexicans.","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2017 ","pages":"8435178"},"PeriodicalIF":1.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/8435178","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35196882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

Randomized Controlled Study Comparing Use of Propofol Plus Fentanyl versus Midazolam Plus Fentanyl as Sedation in Diagnostic Endoscopy in Patients with Advanced Liver Disease. 比较丙泊酚加芬太尼与咪达唑仑加芬太尼在晚期肝病患者诊断内窥镜中的镇静作用的随机对照研究

IF 1.8

International Journal of Hepatology Pub Date : 2017-01-01 Epub Date: 2017-09-26 DOI: 10.1155/2017/8462756

Sameh Abdelkhalik Ahmed, Amal Selim, Nehad Hawash, Ahmed Khaled Tawfik, Mohamed Yousef, Abdelrahman Kobtan, Rehab Badawi, Sally Elnawasany, Reham Abdelkader Elkhouly, Amr Shaaban Hanafy, Fatma H Rizk, Loai Mansour, Sherief Abd-Elsalam

{"title":"Randomized Controlled Study Comparing Use of Propofol Plus Fentanyl versus Midazolam Plus Fentanyl as Sedation in Diagnostic Endoscopy in Patients with Advanced Liver Disease.","authors":"Sameh Abdelkhalik Ahmed, Amal Selim, Nehad Hawash, Ahmed Khaled Tawfik, Mohamed Yousef, Abdelrahman Kobtan, Rehab Badawi, Sally Elnawasany, Reham Abdelkader Elkhouly, Amr Shaaban Hanafy, Fatma H Rizk, Loai Mansour, Sherief Abd-Elsalam","doi":"10.1155/2017/8462756","DOIUrl":"https://doi.org/10.1155/2017/8462756","url":null,"abstract":"Objectives: We aimed to investigate the safety and efficacy of propofol plus fentanyl versus midazolam plus fentanyl as sedative for patients with advanced liver disease presented for gastrointestinal endoscopy.Methods: A total of 100 patients with liver cirrhosis referred for upper endoscopy were enrolled and divided equally in two groups, midazolam plus fentanyl group and propofol plus fentanyl group. All patients were subjected to history taking, estimation of level of sedation, endoscopist rating, and hemodynamic parameters including oxygen saturation, heart rate, mean arterial pressure, incidence of side effect as (bradycardia, hypotension, hypoxia, nausea and vomiting, cough, shivering, or diplopia), time needed for complete recovery, and time needed for discharge.Results: There was no statistical significant difference between the studied groups regarding age, sex, weight, Child-Pugh classification score, type and duration of endoscopic intervention, time needed for complete recovery, or time needed for discharge. Complication rates were similar in both groups except for mean arterial blood pressure which was significantly lower in group of patients receiving propofol and fentanyl (P = 0.001).Conclusion: The use of either propofol or midazolam in combination to fentanyl is effective in sedation of patients with advanced liver diseases presented for upper GIT endoscope. The trial is registered with ClinicalTrials.gov Identifier: NCT03063866.","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2017 ","pages":"8462756"},"PeriodicalIF":1.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/8462756","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35718393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Imaging the Abdominal Manifestations of Cystic Fibrosis. 囊性纤维化的腹部影像学表现。

IF 1.8

International Journal of Hepatology Pub Date : 2017-01-01 Epub Date: 2017-01-29 DOI: 10.1155/2017/5128760

C D Gillespie, M K O'Reilly, G N Allen, S McDermott, V O Chan, C A Ridge

{"title":"Imaging the Abdominal Manifestations of Cystic Fibrosis.","authors":"C D Gillespie, M K O'Reilly, G N Allen, S McDermott, V O Chan, C A Ridge","doi":"10.1155/2017/5128760","DOIUrl":"https://doi.org/10.1155/2017/5128760","url":null,"abstract":"Cystic fibrosis (CF) is a multisystem disease with a range of abdominal manifestations including those involving the liver, pancreas, and kidneys. Recent advances in management of the respiratory complications of the disease has led to a greater life expectancy in patients with CF. Subsequently, there is increasing focus on the impact of abdominal disease on quality of life and survival. Liver cirrhosis is the most important extrapulmonary cause of death in CF, yet significant challenges remain in the diagnosis of CF related liver disease. The capacity to predict those patients at risk of developing cirrhosis remains a significant challenge. We review representative abdominal imaging findings in patients with CF selected from the records of two academic health centres, with a view to increasing familiarity with the abdominal manifestations of the disease. We review their presentation and expected imaging findings, with a focus on the challenges facing diagnosis of the hepatic manifestations of the disease. An increased familiarity with these abdominal manifestations will facilitate timely diagnosis and management, which is paramount to further improving outcomes for patients with cystic fibrosis.","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2017 ","pages":"5128760"},"PeriodicalIF":1.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/5128760","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34775870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Cardiovascular Autonomic Dysfunction in Patients of Nonalcoholic Fatty Liver Disease 非酒精性脂肪肝患者的心血管自主神经功能障碍

IF 1.8

International Journal of Hepatology Pub Date : 2016-12-08 DOI: 10.1155/2016/5160754

M. Kumar, Akanksha Singh, A. Jaryal, P. Ranjan, K. Deepak, Sanjay Sharma, R. Lakshmy, R. Pandey, N. Vikram

{"title":"Cardiovascular Autonomic Dysfunction in Patients of Nonalcoholic Fatty Liver Disease","authors":"M. Kumar, Akanksha Singh, A. Jaryal, P. Ranjan, K. Deepak, Sanjay Sharma, R. Lakshmy, R. Pandey, N. Vikram","doi":"10.1155/2016/5160754","DOIUrl":"https://doi.org/10.1155/2016/5160754","url":null,"abstract":"Aim. The present study was designed to evaluate the heart rate variability (HRV) in nonalcoholic fatty liver disease (NAFLD) and to assess the effect of grade of NAFLD and diabetic status on HRV. Methods. This cross-sectional study included 75 subjects (25 NAFLD without diabetes, 25 NAFLD with diabetes, and 25 controls). Measurements included anthropometry, body composition analysis, estimation of plasma glucose, serum lipids, hsCRP, and serum insulin. HRV analysis was performed in both time and frequency domains. Results. The time and frequency domain indices of overall variability (SDNN, total power) were significantly lower in NAFLD with diabetes as compared to the controls. However, the LF : HF ratio did not differ among the three groups. The variables related to obesity, lipid profile, and glucose metabolism were also higher in NAFLD with diabetes and those with Grade II NAFLD without diabetes, as compared to controls. Multivariate stepwise regression analysis showed a negative correlation between HRV and total cholesterol and fat percentage. Conclusion. The grade of NAFLD as well as diabetic status contributes to the decrease in the cardiovascular autonomic function, with diabetic status rather than grade of NAFLD playing a critical role. Serum lipids and adiposity may also contribute to cardiac autonomic dysfunction.","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"31 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2016-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84487945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 20

A Combination of Leucine, Metformin, and Sildenafil Treats Nonalcoholic Fatty Liver Disease and Steatohepatitis in Mice 亮氨酸、二甲双胍和西地那非联合治疗小鼠非酒精性脂肪肝和脂肪性肝炎

IF 1.8

International Journal of Hepatology Pub Date : 2016-11-30 DOI: 10.1155/2016/9185987

Antje Bruckbauer, J. Banerjee, Lizhi Fu, Fenfen Li, Q. Cao, Xin Cui, R. Wu, Hang Shi, B. Xue, M. Zemel

{"title":"A Combination of Leucine, Metformin, and Sildenafil Treats Nonalcoholic Fatty Liver Disease and Steatohepatitis in Mice","authors":"Antje Bruckbauer, J. Banerjee, Lizhi Fu, Fenfen Li, Q. Cao, Xin Cui, R. Wu, Hang Shi, B. Xue, M. Zemel","doi":"10.1155/2016/9185987","DOIUrl":"https://doi.org/10.1155/2016/9185987","url":null,"abstract":"Sirt1, AMPK, and eNOS modulate hepatic energy metabolism and inflammation and are key players in the development of NASH. L-leucine, an allosteric Sirt1 activator, synergizes with low doses of metformin or sildenafil on the AMPK-eNOS-Sirt1 pathway to reverse mild NAFLD in preclinical mouse models. Here we tested a possible multicomponent synergy to yield greater therapeutic efficacy in NAFLD/NASH. Liver cells and macrophages or an atherogenic diet induced NASH mouse model was treated with two-way and three-way combinations. The three-way combination Sild-Met-Leu increased hepatic fatty acid oxidation and reduced lipogenic gene expression and inflammatory marker in vitro. In mice, Sild-Met-Leu reduced the diet induced increases of ALT, TGFβ, PAI-1, IL1β, and TNFα, hepatic collagen expression, and nearly completely reversed hepatocyte ballooning and triglyceride accumulation, while all two-way combinations had only modest effects. Therefore, these data provide preclinical evidence for therapeutic efficacy of Sild-Met-Leu in the treatment of NAFLD and NASH.","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"21 3 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2016-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90695073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 23

Hyperammonemia Is Associated with Increasing Severity of Both Liver Cirrhosis and Hepatic Encephalopathy 高氨血症与肝硬化和肝性脑病加重有关

IF 1.8

International Journal of Hepatology Pub Date : 2016-10-25 DOI: 10.1155/2016/6741754

Abidullah Khan, M. Ayub, Wazir Mohammad Khan

{"title":"Hyperammonemia Is Associated with Increasing Severity of Both Liver Cirrhosis and Hepatic Encephalopathy","authors":"Abidullah Khan, M. Ayub, Wazir Mohammad Khan","doi":"10.1155/2016/6741754","DOIUrl":"https://doi.org/10.1155/2016/6741754","url":null,"abstract":"Background. Hyperammonemia resulting from chronic liver disease (CLD) can potentially challenge and damage any organ system of the body, particularly the brain. However, there is still some controversy regarding the diagnostic or prognostic values of serum ammonia in patients with over hepatic encephalopathy, especially in the setting of acute-on-chronic or chronic liver failure. Moreover, the association of serum ammonia with worsening Child-Pugh grade of liver cirrhosis has not been studied. Objective. This study was conducted to solve the controversy regarding the association between hyperammonemia and cirrhosis, especially hepatic encephalopathy in chronically failed liver. Material and Methods. In this study, 171 cirrhotic patients had their serum ammonia measured and analyzed by SPSS version 16. Chi-squared test and one-way ANOVA were applied. Results. The study had 110 male and 61 female participants. The mean age of all the participants in years was 42.33 ± 7.60. The mean duration (years) of CLD was 10.15 ± 3.53 while the mean Child-Pugh (CP) score was 8.84 ± 3.30. Chronic viral hepatitis alone was responsible for 71.3% of the cases. Moreover, 86.5% of participants had hepatic encephalopathy (HE). The frequency of hyperammonemia was 67.3%, more frequent in males (N = 81, z-score = 2.4, and P < 0.05) than in females (N = 34, z-score = 2.4, and P < 0.05), and had a statistically significant relationship with increasing CP grade of cirrhosis (χ 2(2) = 27.46, P < 0.001, Phi = 0.40, and P < 0.001). Furthermore, serum ammonia level was higher in patients with hepatic encephalopathy than in those without it; P < 0.001. Conclusion. Hyperammonemia is associated with both increasing Child-Pugh grade of liver cirrhosis and hepatic encephalopathy.","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"48 11 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2016-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88923391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence 慢性肝病选择性手术前使用血小板生成素受体激动剂纠正血小板减少症:当前证据综述

IF 1.8

International Journal of Hepatology Pub Date : 2016-10-09 DOI: 10.1155/2016/1802932

K. Qureshi, Shyam Patel, A. Meillier

{"title":"The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence","authors":"K. Qureshi, Shyam Patel, A. Meillier","doi":"10.1155/2016/1802932","DOIUrl":"https://doi.org/10.1155/2016/1802932","url":null,"abstract":"Patients with chronic liver diseases (CLD) undergo a range of invasive procedures during their clinical lifetime. Various hemostatic abnormalities are frequently identified during the periprocedural work-up; including thrombocytopenia. Thrombocytopenia of cirrhosis is multifactorial in origin, and decreased activity of thrombopoietin has been identified to be a major cause. Liver is an important site of thrombopoietin production and its levels are decreased in patients with cirrhosis. Severe thrombocytopenia (platelet counts < 60–75,000/µL) is associated with increased risk of bleeding with invasive procedures. In recent years, compounds with thrombopoietin receptor agonist activity have been studied as therapeutic options to raise platelet counts in CLD. We reviewed the use of Eltrombopag, Romiplostim, and Avatrombopag prior to various invasive procedures in patients with CLD. These agents seem promising in raising platelet counts before elective procedures resulting in reduction in platelet transfusions, and they also enabled more patients to undergo the procedures. However, these studies were not primarily aimed at comparing bleeding episodes among groups. Use of these agents had some adverse consequences, importantly being the occurrence of portal vein thrombosis. This review highlights the need of further studies to identify reliable methods of safely reducing the provoked bleeding risk linked to thrombocytopenia in CLD.","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"30 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2016-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82121090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 27